Jun-ichi Iga
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Jun-ichi Iga is an Associate Professor at Ehime University in Japan. His research focuses on the efficacy of psychotropic medications, including studies on major depressive disorder and treatment-resistant schizophrenia. Recent publications examine topics such as impulsivity in borderline personality disorder, emotional blunting, and gene expression changes related to mental health conditions.
Recent Grants
Grant: Close
Research on neuropsychiatric disorders in the elderly focusing on the phenomenon of cellular senescence
Open Date: 2022-04-01
Close Date: 2024-03-01
Grant: Close
Blood biomarker for differentiating geriatric depression from Alzheimer's disease
Open Date: 2018-04-01
Close Date: 2021-03-01
Grant: Close
Association between early life adversity and 5HTT mRNA expression and DNA methylation in leukocytes of MDD
Open Date: 2015-04-01
Close Date: 2018-03-01
Grant: Close
Biological diagnostic test for major depressive disorder based on the leukocytes gene expression
Open Date: 2011-04-01
Close Date: 2012-12-01
Grant: Close
Molecular asseessment of PDLIM5 in MDD
Open Date: 2006-04-01
Close Date: 2008-03-01
Articles (35)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Background: Overall, 20% of patients with major depressive disorder (MDD) are treatment-resistant and do not respond to multiple antidepressant monotherapies. For such patients, augmentation therapy with antipsychotics is one of the therapeutic options. However, the mechanism of augmentation therapy is essentially unknown. Aim: This study aimed to elucidate the mechanism of brexpiprazole (BREX) augmentation at gene expression levels. Methods: Vehicle, escitalopram (ES), BREX, and ES + BREX (augmentation therapy) were administered to mouse neuroblastoma (Neuro2a) cells and submitted to RNA-sequencing. Gene expressions were also measured in the whole blood of MDD patients and the frontal cortices and hippocampi of mice after treatment for 20 days. Results: On RNA-seq and gene ontology analyses, upregulation of mitochondria (MT)-related genes was confirmed by quantitative Polymerase Chain Reaction (PCR). These upregulated genes were successfully validated in both Neuro2a and Caco2 cells. Decreased MT-ATP8 expression was found in the whole blood of MDD patients. Furthermore, changes in MT-mRNA expression were confirmed in the frontal cortices and hippocampi of mice with augmentation therapy. Conclusions: BREX augmentation modified MT-mRNA expressions in both in vitro and in vivo experiments. This may be a key finding in improving our understanding of MDD pathogenesis and clinical practice.
Year:
2025
Background and hypothesis The rate of antipsychotic polypharmacy is high. One risk factor for antipsychotic polypharmacy may be the severity of schizophrenia, including treatment-resistant schizophrenia (TRS). We hypothesized that the institutions that are able to prescribe clozapine present differences in pharmacological treatment even before TRS is diagnosed. Study Design A total of 8155 patients with schizophrenia were divided into the clozapine-available institution (CAI) group and the clozapine-unavailable institution (CUI) group. The psychotropic prescription rates at discharge were compared between the two groups. Furthermore, to investigate whether the diagnosis of TRS subgroups influenced treatment efficacy, we compared CAIs and CUIs with descriptions of subgroups with TRS (DSTRS) and those without descriptions of subgroups with TRS (NDSTRS). Results Compared to the CUI group, the rates of both antipsychotic monotherapy (58.3% vs. 50.7%; P = 2.4 × 10−7) and antipsychotic monotherapy without the concomitant use of other psychotropics (20.4% vs. 15.6%; P = 3.8 × 10−5) were significantly higher in the CAI group. The rate of antipsychotic monotherapy in the CAI with DSTRS group (63.3%) was significantly higher than that in the CAI with NDSTRS group (54.5%; P = 1.4 × 10−12), the CUI with DSTRS group (49.6%; P = 4.9 × 10−9), and the CUI with NDSTRS group (50.9%; P = 2.0 × 10−8). The rate of antipsychotic monotherapy without the concomitant use of other psychotropics in the CAI with DSTRS group (22.6%) was also significantly higher than that in the CAI with NDSTRS group (18.7%; P = 4.7 × 10−4), the CUI with DSTRS group (15.9%; P = 5.5 × 10−4), and the CUI with NDSTRS group (15.2%; P = 8.0 × 10−5). There was no significant difference in these rates between the other groups. Conclusions Both the availability of clozapine prescriptions and the precise diagnosis of TRS subgroups at discharge can promote the development of an organizational culture that facilitates the treatment of patients with schizophrenia.
Year:
2025
Year:
2025
Aim Recent studies have implicated autophagy in both weight regulation and depression. This study aimed to investigate the relationship between stress‐induced weight loss and autophagy‐related gene expression in a mouse model of depression. Method Male C57BL/6 mice were subjected to a chronic immobilization stress (CIS) protocol for 14 days to induce depressive‐like behavior. Body weight was measured before and after the CIS, and depressive‐like behavior was assessed using the tail suspension test (TST). The expression levels of autophagy‐related genes ( Atg5 , Atg7 , Atg12 , Becn1 , Mmp9 , Fkbp5 , and Map1lc3b ) in the hippocampus and midbrain were evaluated using reverse transcription‐quantitative PCR (RT‐qPCR). Serum cortisol levels were also measured. Results The CIS resulted in significant weight loss and increased immobility time in the TST, indicating depressive‐like behavior. Serum cortisol levels were not different between CIS‐depression model and control mice. In the hippocampus, the expression levels of Fkbp5 , Mmp9 , and Map1lc3b were significantly higher in CIS‐depression model mice than in control mice. In the midbrain, the expression levels of Fkbp5 and Mmp9 were significantly higher in CIS‐depression model mice than in control mice. Increased autophagy‐related gene expressions in CIS‐depression model mice were consistent with the previous studies in the postmortem brains of patients with depression. A significant negative correlation was also found between Fkbp5 mRNA expression in the hippocampus and the weight change ratio before and after the CIS. Conclusion The findings suggest that enhanced autophagy may be related to the pathology of depression and that Fkbp5, an autophagy regulator, mediates stress‐induced weight loss.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (13)
Akihide Takeuchi
Professor & Chairperson
Kyoto Prefectural University of Medicine
Motohiro Okada
Hirosaki University
Shu-ichi Ueno
Professor
Ehime University Graduate School of Medicine
Tetsuya Maeda
Iwate Medical University
Tomoyasu Wakuda
Senior Assistant Professor
Hamamatsu University School of Medicine
Kentaro Kawabe
Ehime University
Shinichiro Ochi
Ehime University
Masakatsu Yamashita
-
Yoshihiko Furuta
Kyushu University
Takanori Honda
Researcher
Kyushu University Graduate School of Medical Sciences
Kenta Ide
University of Occupational and Environmental Health Japan
Yusuke Inoue
Kyoto University
Kenjiro Ono
Kanazawa University Graduate School of Medical Sciences
Make your next move.
Prepare your application
Review drafts before you send them.